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Background: Radical prostatectomy is used to treat patients with clinically localized prostate cancer, but there have
been few reports of its use in locally advanced disease. We evaluated the long-term results of radical prostatectomy
and immediate adjuvant androgen deprivation therapy in Japanese patients with pT3N0M0 prostate cancer.
Methods: We retrospectively reviewed 128 patients with pT3N0M0 prostate cancer who underwent radical
prostatectomy at our institute from 2000 to 2006. All pT3N0 patients were treated with adjuvant androgen deprivation
therapy shortly after radical prostatectomy. Immediate adjuvant androgen deprivation therapy was continued for at
least 5 years. Twenty-three were excluded because of preoperative hormonal therapy, missing data, or others. Death
from any cause, death from prostate cancer, clinical recurrence and hormone-refractory biochemical progression were
analyzed by Kaplan-Meier graphs. Relative risks of progression were estimated using Cox proportional hazards models
with 95% confidence intervals.
Results: The 10-year hormone-refractory biochemical progression-free survival rate was 88.3% and the cancer-specific
survival rate was 96.3% after a median follow-up period of 8.2 years (range 25.6-155.6 months). Higher clinical stage
(p = 0.013), higher Gleason score at biopsy (p = 0.001), seminal vesicle invasion (p = 0.003) and microlymphatic invasion
(p = 0.006) were predictive factors for hormone-refractory biochemical progression by univariate analyses. Multivariate
analyses identified Gleason score at biopsy (p = 0.027) and seminal vesicle invasion (p = 0.030) as independent
prognostic factors for hormone-refractory biochemical progression. None of the patients with clinical T1 cancers
(n = 20), negative surgical margin (n = 12), or negative perineural invasion (n = 11) experienced hormone-refractory
biochemical progression.
Conclusions: Radical prostatectomy with immediate adjuvant androgen deprivation therapy may be a valid
treatment option for patients with pT3N0M0 prostate cancer.
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Radical prostatectomyBackground
Tumor cell penetration of the prostatic capsule or inva-
sion of the seminal vesicle is recognized as locally ad-
vanced prostate cancer of pathological T3N0. Patients
with pT3N0 prostate cancers have the potential to suffer
from disease relapse, and radical prostatectomy alone* Correspondence: hfukuhara-jua@umin.ac.jp
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unless otherwise stated.may fail to achieve a cure. The introduction of prostate
specific antigen (PSA) assays means that more patients
now undergo radical prostatectomy at earlier stages. How-
ever, pT3 disease still occurs in 25–58% of clinical T1 and
T2 prostate cancer patients [1-4]. Although the manage-
ment of patients with pT3 prostate cancer remains con-
troversial, some reports recommend the use of adjuvant
therapies in these patients [5-9]. Few studies have reported
treatment outcomes of pT3 cancers, but some clinico-
pathologic factors, such as higher Gleason score, higherd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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be prognostic factors associated with poorer outcome
[10-13]. However, to the best of our knowledge, there have
been few reports of pT3N0 patients treated with adjuvant
hormonal therapy, and more outcome data and accurate
information are needed for these patients. We therefore
analyzed clinical data from patients with pT3N0 prostate
cancer to obtain detailed information and long-term
outcome data. Importantly, a pathologic diagnosis of
pT3N0M0 cancer is not necessarily accurate in patients
who have undergone preoperative therapy, and this
study therefore only included patients who had not re-
ceived any preoperative treatment.
Methods
We retrospectively reviewed 128 patients with pT3N0M0
out of a total of 431 patients with prostate cancer who
underwent radical prostatectomy at our hospital from
January 2000 to December 2006. These patients were se-
lected because immediate adjuvant hormonal therapy was
applied in patients with pT3N0M0 prostate cancer during
this period. Twenty-three patients were excluded from the
analysis; four because of incomplete data, 12 because they
had received preoperative hormonal therapy and seven be-
cause they had received bicalutamide only or estramustine
as hormonal therapy. Data from the remaining 105 pa-
tients were analyzed. Bilateral obturator lymph nodes were
dissected in all patients at radical prostatectomy. Immedi-
ate adjuvant androgen deprivation therapy was started
within 12 weeks of radical prostatectomy. Undetectable
PSA levels or PSA nadir were not required to be con-
firmed following radical prostatectomy. Clinical diagnosis
was defined according to the 2009 TNM guidelines based
on a digital rectal examination (DRE), transrectal ultrason-
ography, biopsy results, computed tomography scans and/
or magnetic resonance imaging, and bone scintigraphy.
All specimens were reviewed by a single pathologist. After
radical prostatectomy, patients were followed-up at
1-month intervals for the first 3 months following surgery,
then at 3-month intervals for 5 years, and finally at 3–6-
month intervals thereafter. Follow-up examinations in-
cluded measurement of PSA levels, and a DRE, computed
tomography scan, magnetic resonance imaging or bone
scintigraphy in the event of suspected disease recurrence.
Immediate adjuvant therapy included surgical orchiec-
tomy, administration of luteinizing hormone-releasing
hormone (LHRH) analogs, and combined androgen
blockade consisting of orchiectomy or an LHRH ana-
log together with anti-androgens. Immediate adjuvant an-
drogen deprivation therapy was continued for at least 5
years after radical prostatectomy. Salvage additive or al-
tered hormonal therapies were initiated when the PSA
level rose rapidly by >0.4 ng/ml, or when it rose consis-
tently by >0.2 ng/ml for more than three consecutivevisits. Salvage additive or altered hormonal therapy in-
cluded: 1) combined androgen blockade consisting of
orchiectomy or LHRH analog with bicalutamide; 2) suspen-
sion of bicalutamide to confirm the effects of anti-androgen
withdrawal; 3) estramustine; and 4) dexamethasone.
Hormone-refractory biochemical progression was defined
as a PSA level >0.2 ng/ml despite the above hormonal ther-
apies. Clinical recurrence was defined as recognizable dis-
ease relapse on imaging examination. Clinical recurrence
was treated by salvage radiation therapy. This study was ap-
proved by the Ethics Committee, Graduate School of Medi-
cine and Faculty of Medicine, The University of Tokyo.
The study end points were death from any cause, death
from prostate cancer, clinical recurrence, and hormone-
refractory biochemical progression. These end points were
analyzed by plotting Kaplan-Meier graphs and comparing
them according to each clinicopathologic factor using log-
rank tests. Relative risks for hormone-refractory bio-
chemical progression according to each clinicopatho-
logic factor were estimated using the Cox proportional
hazards models with 95% confidence intervals. All stat-
istical analyses were performed using JMP version 9
(SAS Institute, Cary, NC, USA) and differences were
considered statistically significant at p < 0.05. The fol-
lowing clinicopathologic factors were evaluated: age at
radical prostatectomy, preoperative PSA level, preopera-
tive T stage (clinical stage), Gleason score of the biopsy
specimen, seminal vesicle invasion (representing stage
pT3b), surgical margin of operation specimen, micro-
lymphatic invasion, microvascular invasion, perineural
invasion, and Gleason score.
Results
The clinical and pathological data for all 105 patients are
shown in Table 1. The median age at surgery was
67.0 years and the median preoperative PSA level was
15.1 ng/ml (range 3.5–160.7, with lower and upper quar-
tile values of 8.18 and 24.9). The median number of
lymph nodes removed was 7.0 (range 2–19). A total of
43% of patients were underestimated preoperatively as
having stage T1 (n = 20; 19.0%) or T2 (n = 25; 23.8%) tu-
mors. Regarding the Gleason score at biopsy, 38 (36.2%)
patients had a score of ≥8. Seminal vesicle invasion
(pT3b) was detected in 42 patients (40.0%). Microlym-
phatic and microvascular invasions were detected in 33
(31.4%) and 51 (48.6%) patients, respectively. Immediate
adjuvant androgen deprivation therapy consisted of an-
drogen suppression with orchiectomy (n = 17), LHRH
analog (n = 64), combined androgen blockade with orchiec-
tomy or LHRH analog and bicalutamide or other anti-
androgens (n = 24). Three patients changed their hormonal
therapies during follow-up because of adverse events.
The median follow-up period was 98.7 months (range
25.6–155.6). During the follow-up period, eleven patients
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gression. Seven patients experienced clinical recurrence
and received salvage radiation therapy to clinically recur-
rent foci. Three (2.9%) patients died of prostate cancer
and eight (7.6%) died of other causes. The 5- and 10-year
cancer-specific survival rates were 98.1 and 96.3%, re-
spectively. The 5- and 10-year hormone-refractory bio-
chemical progression-free survival rates were 94.3 and
88.3%, with 5- and 10-year clinical recurrence-free survival
rates of 96.0 and 93.0%, respectively. The 10-year esti-
mated overall survival rate was 85.7%.
Table 2 shows the hormone-refractory biochemical
progression-free survival rates calculated from Kaplan-
Meier graphs, according to each clinicopathologic param-
eter. Univariate analyses using Cox proportional hazard
models indicated that higher clinical stage (p = 0.013),
higher Gleason score at biopsy (p = 0.001), seminal vesicle
invasion (p = 0.003) and microlymphatic invasion (p =
0.006) were predictive factors for hormone-refractory
biochemical progression (Table 2). Multivariate analysesTable 1 Patient characteristics (n = 105)
Parameter n (%)
Age, years (median 67.0) <65 37 35.2
≥65 68 64.8
PSA, ng/ml [median 14.3 (2.4 − 160.7)] <10 35 33.3
10 ~ 20< 36 34.3
20 ~ 50< 23 21.9
≥50 11 10.5




Gleason score at biopsy 5 ~ 6 34 32.4
7 33 31.4
≥8 38 36.2
Seminal vesicle invasion − 63 60.0
+ 42 40.0
Surgical margin − 12 11.4
+ 93 88.6
Microlymphatic invasion − 72 68.6
+ 33 31.4
Microvascular invasion − 54 51.4
+ 51 48.6
Perineural invasion − 11 10.5
+ 94 89.5
Gleason score at prostatectomy 5 ~ 6 16 15.2
7 54 51.4
≥8 35 33.3identified Gleason score at biopsy and (p = 0.027) semi-
nal vesicle invasion (p = 0.030) as independent prognostic
factors for hormone-refractory biochemical progression
(Table 2).
Discussion
Despite widespread use of PSA measurement, pT3N0M0
prostate cancer still occurs in 25–58% of clinical T1 and
T2 prostate cancer patients [1-4]. In the current study,
about half of the patients (43%) were also understaged
preoperatively as having organ-confined disease. Although
pT3N0M0 prostate cancer is not rare, there have been few
reports of treatment outcomes in these patients. The opti-
mal postsurgical management for patients with such un-
favorable pathological features remains questionable. We
therefore analyzed clinical data from patients with
pT3N0M0 prostate cancer to obtain detailed information
and long-term outcome data.
The patients in this study achieved 5- and 10-year
cancer-specific survival rates of 98.1 and 96.3%, respect-
ively, and 5- and 10-year hormone-refractory biochem-
ical progression-free survival rates of 94.3 and 88.3%,
respectively. In a previous study, Inagaki et al. reported
1- and 3-year biochemical progression-free survival rates
of 53.7 and 34.1% in 106 patients with pT3N0M0 pros-
tate cancer treated with radical prostatectomy alone,
after a mean follow-up of 1.5 years [10]. Delongchamps
et al. and Briganti et al. reported 5-year biochemical
progression-free survival rates of 48 and 45.0% in 147
and 500 patients with pT3N0M0 prostate cancer, re-
spectively, treated with radical prostatectomy alone, after
median follow-up periods of 5 and 3.9 years [11,12].
Thompson et al. reported 10-year metastasis-free sur-
vival rates and overall survival rates of 61 and 66% in
211 patients with pT3N0M0 prostate cancer treated with
radical prostatectomy, even after salvage radiotherapy [5].
Single-modality therapy involving surgery alone might be
of limited use in patients with stage pT3N0M0 prostate
cancer, and a multimodal approach may be more benefi-
cial. Three studies found that adjuvant radiotherapy after
radical prostatectomy reduced the risk of subsequent bio-
chemical recurrence in randomized clinical trials [5-7].
Thompson et al. reported a survival benefit of adjuvant
radiotherapy, with a 10-year estimated survival rate of
74% in 214 patients with pT2-3 N0 prostate cancer treated
with adjuvant radiotherapy, compared with 66% in 211
cases treated with surgery alone, after median follow-up
period of 12.5 years [5,6]. This cohort included patients
with pT3N0 and pT2N0 with positive surgical margins,
and patients were allowed to receive salvage hormonal
therapy during the follow-up period. Regarding the com-
bination of radical prostatectomy and adjuvant hormonal
therapy, Dorff et al. reported favorable outcomes in an in-
terim report of a prospective randomized trial of 481
Table 2 Hormone refractory biochemical progression-free survival according to each clinicopathological parameter
Univariate and multivariate analyses for hormone refractory biochemical-progression free survival rates
Parameter Hormone refractory biochemical
progression-fee survival rates
Univariate analysis Multiivariate analyses
5 years 10 years HR† 95% CI†† p HR† 95% CI†† p
Age, years (median 67.0) <65 94.6 89.9
≥65 94.1 87.6 0.687
PSA, mg/ml [median 15.1 (3.5−160.7)] <10 97.1 97.1 1
10-20< 88.9 80.8 6.18 1.1, 116.8 0.043
20-50< 100.0 100.0 0.0 0,. 0.315
≥50 90.9 60.6 12.9 1.9, 254.0 0.008
Clinical stage T1,2 100.0, 100.0 100.0, 88.9 1 1
T3~4 90.0 84.8 7.47 1.4, 137.1 0.013* 3.65 0.7, 68.6 0.161
Gleason score at biopsy 5~7 98.5 98.3 1 1
≥8 86.8 70.3 8.38 2.2, 55.0 0.001* 4.73 1.2, 31.7 0.027*
Seminal vesicle invasion − 98.4 98.4 1 1
+ 88.1 73.1 7.42 1.9, 48.7 0.003* 4.53 1.1, 30.1 0.030*
Surgical margin − 100.0 100.0
+ 93.6 86.7 0.183
Microlymphatic invasion − 97.2 95.0 1 1
+ 87.9 74.4 5.33 1.5, 24.7 0.006* 2.18 0.9, 12.8 0.140
Microvascular invasion − 96.3 90.5
+ 92.2 85.6 0.468
Perineural invasion − 100.0 100.0
+ 93.6 86.7 0.242
Gleason score at prostatectomy 5−7 95.7 89.6
≥8 91.4 71.4 0.114
†Hazard ratio by Cox proportional-hazard models
††Confidence interval
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of T3 and 16% of N1 patients [14]. Although longer obser-
vation periods are awaited, they reported 5-year biochem-
ical progression-free and overall survival rates of 92.5 and
95.5%, respectively, in patients treated with adjuvant hor-
monal therapy consisting of goserelin and bicalutamide,
after a median observation period of 4.4 years. Some stud-
ies reported encouraging results in more challenging pa-
tients with more severe pathological stages. Spahn et al.
reported on 173 patients with pT3N0-1 tumors, including
43.3% of N1, who had undergone prostatectomy [15].
They reported an 8-year cancer-specific survival rate of
86.3% and an overall survival rate of 77.3% after a median
observation period of 5.7 years in patients treated with ad-
juvant hormonal therapy comprising an LHRH analog
with or without flutamide. Siddiqui et al. reported an
advantage of adjuvant hormonal therapy with an LHRH
analog, bilateral orchiectomy, or anti-androgens in a retro-
spective study of 191 pT3bN0M0 prostate cancer patients
[9]. They found that, although the overall survival rate
was similar to that in the matched control cohort, thebiochemical progression-free and cancer specific sur-
vival rates were improved, with 10-year biochemical
progression-free and cancer-specific survival rates of 60
and 94%, respectively, after a median follow-up of 10 years
[9]. In accordance with this previous report, subgroup ana-
lyses of pT3bN0 patients in the current study demonstrated
excellent outcomes, with 5- and 10-year cancer-specific sur-
vival rates of 95.1 and 90.8%, respectively. These results in-
dicate that the combination of radical prostatectomy and
adjuvant androgen deprivation therapy may produce excel-
lent outcomes in patients with pT3N0M0 prostate cancer.
The current study achieved a 10-year cancer-specific
survival rate of 96.3% and a 10-year estimated overall sur-
vival rate of 85.7% after a median follow-up period of
8.2 years. These survival rates were higher than those in
previous reports, which may require an explanation. Im-
mediate commencement of adjuvant androgen deprivation
therapy after radical prostatectomy, and its comparatively
long duration (at least 5 years), may have contributed to
the beneficial effect. Supportive treatment strategies, such
as prompt adjustment or alteration of hormonal therapy
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have improved the treatment efficacy. It is also possible
that Japanese men are more sensitive than other ethnic
groups to hormonal therapy after radical prostatectomy.
Akaza et al. reported 5- and 10-year cancer-specific sur-
vival rates of 90 and 69%, respectively, in 68 Japanese pa-
tients with clinical T3N0M0 tumors who were treated
with hormonal therapy alone [16]. However, Ueno et al.
reported 5- and 8-year progression-free survival rates of
59.8 and 48.1%, respectively, in 245 Japanese patients with
clinical T3N0M0 cancers treated with combined androgen
blockade (63.5%) or castration [17].
The Asia Consensus Statement 2013 in the NCCN
Clinical Practice Guidelines in Prostate Cancer states
that androgen deprivation is a candidate treatment op-
tion for post-radical prostatectomy recurrence in Asian
patients negative for distant metastasis. The results of
the current study suggest that a treatment strategy con-
sisting of radical prostatectomy and immediate adjuvant
androgen deprivation therapy may offer favorable can-
cer control in Japanese patients with pT3N0M0 prostate
cancer. This strategy was also feasible and well tolerated.
Immediate adjuvant androgen deprivation therapy thus rep-
resents an attractive option for patients with pT3N0M0
prostate cancer.
Few studies have reported on prognostic factors in pa-
tients with pT3 prostate cancer. The current study found
that higher clinical stage, higher Gleason score at biopsy,
and seminal vesicle and microlymphatic invasion were
unfavorable factors, and multivariate analyses identified
seminal vesicle invasion and Gleason score at biopsy as
independent prognostic factors for hormone-refractory
biochemical progression. Interestingly, no patients with
clinical T1 tumors (n = 20), negative surgical margin
(n = 12), or negative perineural invasion (n = 11) expe-
rienced hormone-refractory biochemical progression.
In partial agreement with our results, previous studies
identified Gleason score, PSA, seminal vesicle invasion
and lymphovascular invasion as prognostic predictors in
patients with pT3N0 stage prostate cancer undergoing rad-
ical prostatectomy [10-13].
The limitations of this study included its retrospective na-
ture and the relatively small sample size. Further investiga-
tions, including prospective studies, are needed to compare
the additive effects of multimodal therapies in patients with
pT3N0, to allow the better selection of patient populations
most likely to benefit from treatment. The current study in-
dicated a significant hazard ratio for seminal vesicle inva-
sion or with higher Gleason score at biopsy, suggesting that
patients with pT3b or with higher Gleason score may be
the leading candidates for such studies.
These findings were based on pathologic results. The
majority of the patients included in the study were con-
sidered to have lower grade and stage at diagnosis, andT3N0 was only diagnosed after radical prostatectomy.
These results suggest that radical prostatectomy is a
reasonable option for the initial treatment of prostate
cancer, and allow for the better selection of patients
who will require additional therapies.
Conclusions
Radical prostatectomy with immediate adjuvant androgen
deprivation therapy may be a valid treatment option for
patients with pT3N0 prostate cancer.
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